Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592530 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRSMN1; SMN2ACACBACACA | |
| SCHEMBL5175887 | 0.81 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3598740 | 0.81 | KDM4E (0.45) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3598735 | 0.81 | KDM4E (0.45) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3828585 | 0.79 | ALDH1A1 (0.78) | ALDH1A1TSHRSMN1; SMN2HPGDLMNA | |
| SCHEMBL15322429 | 0.78 | HPGD (0.63) | ALDH1A1TSHRSMN1; SMN2HPGDLMNA | |
| SCHEMBL13609481 | 0.77 | CHRNB2 (0.49) | ALDH1A1TSHRSMN1; SMN2ACACBACACA | |
| SCHEMBL4668338 | 0.77 | HRH3 (0.48) | ALDH1A1TSHRSMN1; SMN2HPGDMEN1 | |
| SCHEMBL5195299 | 0.76 | HRH3 (0.51) | ALDH1A1TSHRHPGDLMNAHRH3 | |
| SCHEMBL2677613 | 0.76 | ALDH1A1 (0.72) | ALDH1A1TSHRSMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | claimed |
| CN-101365698-A | 2-urea-4-phenylthiazole derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2009-02-11 | — | — | CN | claimed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | claimed |
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| CN-101365698-A | 2-urea-4-phenylthiazole derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2009-02-11 | — | — | CN | disclosed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PKD2, QPCT, CCNT2 | ALDH1A1 838/4885TSHR 852/4885SMN1; SMN2 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.